Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 68

Sort by

Sort Order Select

Journal Articles

Forimtamig, a novel GPRC5D-targeting T-cell bispecific antibody with a 2+1 format, for the treatment of multiple myeloma

Blood blood.2024025987.

https://doi.org/10.1182/blood.2024025987

Published: 2024

Includes: Supplemental data

Journal Articles

CD19-CD28: an affinity-optimized CD28 agonist for combination with glofitamab (CD20-TCB) as off-the-shelf immunotherapy

Blood (2024) 143 (21): 2152–2165.

https://doi.org/10.1182/blood.2023023381

Published: 2024

Includes: Supplemental data

Journal Articles

Ibrutinib-based therapy reinvigorates CD8 + T cells compared to chemoimmunotherapy: immune monitoring from the E1912 trial

Despoina Papazoglou, Xin Victoria Wang, Tait D. Shanafelt, Connie E. Lesnick, Nikolaos Ioannou, Giulia De Rossi, Sylvia Herter, Marina Bacac, Christian Klein, Martin S. Tallman, Neil E. Kay, Alan G. Ramsay

Blood (2024) 143 (1): 57–63.

https://doi.org/10.1182/blood.2023020554

Published: 2024

Includes: Supplemental data

Journal Articles

Early Intervention with Celmods, but Not Imids, Prevents Relapse to Forimtamig Driven By GPRC5D-Negative Myeloma Cells

Jan Eckmann, Carina Hage, Lechner Stefanie, Christa Bayer, Christian Klein, Pablo Umana

Blood (2023) 142 (Supplement 1): 4659.

https://doi.org/10.1182/blood-2023-174253

Published: 2023

Journal Articles

Fine Tuning Bispecific Activity in CLL: Harmonizing a CD19/20-T Cell Bispecific with a CD28 or 4-1BBL Costimulatory Bispecific

Giulia Petra Rappa, Monika Sponheimer, Gerulf Hänel, Anne-Sophie Neumann, Nora Philipp, Koorosh Korfi, Sylvia Herter, Johannes Sam, Franz Schuler, Christian Klein, Marina Bacac, Pablo Umana, Marion Subklewe

Blood (2023) 142 (Supplement 1): 2058.

https://doi.org/10.1182/blood-2023-180785

Published: 2023

Journal Articles

Optimizing Ex-Vivo Expanded NK Cell- Mediated Cellular Cytotoxicity By Obinutuzumab Combined with NKTR-255 in Burkitt Lymphoma (BL)

Yaya Chu, Keira Foley, Meijuan Tian, Kayleigh Klose, Jessica Ayala-Cuesta, Dean Anthony Lee, Mario Marcondes, Christian Klein, Mitchell S. Cairo

Blood (2023) 142 (Supplement 1): 2063.

https://doi.org/10.1182/blood-2023-181996

Published: 2023

Journal Articles

Adaptor Anti-P329G CAR T Cells for Modular Targeting of AML

Sophia Stock, Thaddaeus Strzalkowski, Adrian Gottschlich, Lisa Rohrbacher, Luisa Fertig, Vivien D. Menkhoff, Marlena Surowka, Peter Bruenker, Diana Darowski, Stefan Endres, Michael von Bergwelt-Baildon, Marion Subklewe, Christian Klein, Sebastian Kobold

Blood (2023) 142 (Supplement 1): 4805.

https://doi.org/10.1182/blood-2023-182864

Published: 2023

Journal Articles

RG6333 (CD19-CD28), a CD19-Targeted Affinity-Optimized CD28 Bispecific Antibody, Enhances and Prolongs the Anti-Tumor Activity of Glofitamab (CD20-TCB) in Preclinical Models

Blood (2022) 140 (Supplement 1): 3142–3143.

https://doi.org/10.1182/blood-2022-159941

Published: 2022

Journal Articles

CD25 Targeting Eliminates Regulatory T Cells and CD25+ Blasts in Acute Myeloid Leukemia

Laurene Pousse, Bruno C. Medeiros, Koorosh Korfi, Marco Berrera, Nadine Kumpesa, Vera Griesser, Jan Eckmann, Vaios Karanikas, Christian Klein, Maria Amann

Blood (2022) 140 (Supplement 1): 6291–6292.

https://doi.org/10.1182/blood-2022-158189

Published: 2022

Journal Articles

Pharmacologic Inhibitors of STAT3 or BCL6 Transcriptional Function Sensitize Lymphoma Cells to the Novel PD-1 Cis-Targeted PD1-IL2v Immunocytokine in a Murine Model

Weiyuan Wang, Foster Burton, Sylvia Herter, Laura Codarri Deak, Christian Klein, David Frank

Blood (2022) 140 (Supplement 1): 8835–8836.

https://doi.org/10.1182/blood-2022-167853

Published: 2022

Journal Articles

RG6234: A Novel 2:1 GPRC5D T Cell Bispecific Antibody Exhibits Best in Class Potential for the Treatment of Multiple Myeloma As a Monotherapy and in Combination

Blood (2022) 140 (Supplement 1): 2091–2092.

https://doi.org/10.1182/blood-2022-157485

Published: 2022

Journal Articles

Targeting intracellular WT1 in AML with a novel RMF-peptide-MHC-specific T-cell bispecific antibody

Blood (2021) 138 (25): 2655–2669.

https://doi.org/10.1182/blood.2020010477

Published: 2021

Includes: Supplemental data

Journal Articles

Augmenting Efficacy of T-Cell Bispecific Antibodies in AML through a Tumor Stroma-Targeted 4-1BB Agonist

Gerulf Hänel, Anne-Sophie Neumann, Vesna Pulko, Christina Claus, Alexandra Leutbecher, Anetta Marcinek, Nora Zieger, Veit L Buecklein, Pablo Umana, Christian Klein, Marion Subklewe

Blood (2021) 138 (Supplement 1): 1178.

https://doi.org/10.1182/blood-2021-146762

Published: 2021

Journal Articles

RG6076 (CD19-4-1BBL): CD19-Targeted 4-1BB Ligand Combination with Glofitamab As an Off-the-Shelf, Enhanced T-Cell Redirection Therapy for B-Cell Malignancies

Sylvia Herter, PhD, Johannes Sam, PhD, Claudia Ferrara Koller, PhD, Sarah Diggelmann, Esther Bommer, Anne Schönle, Christina Claus, PhD, Marina Bacac, PhD, Christian Klein, PhD, Pablo Umana, PhD

Blood (2020) 136 (Supplement 1): 40.

https://doi.org/10.1182/blood-2020-134782

Published: 2020

Journal Articles

Long-Term Results from a Phase 1b Study of Avadomide in Combination with Obinutuzumab in Patients with Relapsed and/or Refractory B-Cell Non-Hodgkin Lymphoma

Jean-Marie Michot, MD, Reda Bouabdallah, MD, Jeanette K. Doorduijn, MD PhD, Carola Boccomini, MD, Marie José Kersten, MD PhD, Annalisa Chiappella, Pier Luigi Zinzani, MD, Gilles Salles, MD PhD, Fontanet Bijou, MD, Mei Hentrup, BSN, BS, So Hyun Rhee, PharmD, Patrick Hagner, PhD, Christian Klein, PhD, Michael Pourdehnad, Kristen Hege, MD, Juergen Dobmeyer, MD, Zariana Nikolova, MD PhD, Vincent Ribrag, MD

Blood (2020) 136 (Supplement 1): 41–42.

https://doi.org/10.1182/blood-2020-134949

Published: 2020

Journal Articles

Lymphoma Microenvironment Deconvolution Links M1 Macrophage Infiltration to Clinical Outcome in Diffuse Large B-Cell Lymphoma

Mark Yan, Yi Meng Chang, Vibha Raghavan, Estella Dong, Christian Klein, PhD, Tina G Nielsen, Joseph N Paulson, Katerina Hatzi

Blood (2020) 136 (Supplement 1): 29–30.

https://doi.org/10.1182/blood-2020-134867

Published: 2020

Journal Articles

Optimizing Ex-Vivo Expanded NK Cell- Mediated Antibody-Dependent Cellular Cytotoxicity (ADCC) Combined with NKTR-255 in Chronic Lymphocytic Leukemia (CLL), Follicular Lymphoma (FL), and Burkitt Lymphoma (BL)

Yaya Chu, PhD, Susiyan Jiang, MS, Jian Jiang, MD, Meijuan Tian, PhD, Dean Anthony Lee, MD PhD, Loui Madakamutil, Mario Q. Marcondes, MDPhD, Christian Klein, PhD, Mitchell S Cairo, MD

Blood (2020) 136 (Supplement 1): 23–24.

https://doi.org/10.1182/blood-2020-139822

Published: 2020

Journal Articles

Polatuzumab Vedotin, an Antibody-Drug Conjugate Targeting CD79b, Is a Highly Active Agent Against Burkitt Lymphoma and Primary Mediastinal B-Cell Lymphoma

Anthony N. Audino, MD, Matthew J. Barth, MD, Aradhana Tiwari, PhD, Dina Edani, MS, Janet Ayello, MS, MT(ASCP), Lauren Harrison, RN, MSN, Erin Morris, RN, BSN, Jessica C. Hochberg, MD, Stanton Goldman, MD, Christian Klein, PhD, Mitchell S Cairo, MD

Blood (2019) 134 (Supplement_1): 3963.

https://doi.org/10.1182/blood-2019-128580

Published: 2019

Journal Articles

Targeting Intracellular WT1 in AML Utilizing a T Cell Bispecific Antibody Construct: Augmenting Efficacy through Combination with Lenalidomide

Blood (2019) 134 (Supplement_1): 4450.

https://doi.org/10.1182/blood-2019-130121

Published: 2019

Journal Articles

Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia

Blood (2019) 133 (26): 2765–2775.

https://doi.org/10.1182/blood-2019-01-896290

Published: 2019

Includes: Supplemental data

NARROW

Forimtamig, a novel GPRC5D-targeting T-cell bispecific antibody with a 2+1 format, for the treatment of multiple myeloma

CD19-CD28: an affinity-optimized CD28 agonist for combination with glofitamab (CD20-TCB) as off-the-shelf immunotherapy

Ibrutinib-based therapy reinvigorates CD8 + T cells compared to chemoimmunotherapy: immune monitoring from the E1912 trial

Early Intervention with Celmods, but Not Imids, Prevents Relapse to Forimtamig Driven By GPRC5D-Negative Myeloma Cells

Fine Tuning Bispecific Activity in CLL: Harmonizing a CD19/20-T Cell Bispecific with a CD28 or 4-1BBL Costimulatory Bispecific

Optimizing Ex-Vivo Expanded NK Cell- Mediated Cellular Cytotoxicity By Obinutuzumab Combined with NKTR-255 in Burkitt Lymphoma (BL)

Adaptor Anti-P329G CAR T Cells for Modular Targeting of AML

RG6333 (CD19-CD28), a CD19-Targeted Affinity-Optimized CD28 Bispecific Antibody, Enhances and Prolongs the Anti-Tumor Activity of Glofitamab (CD20-TCB) in Preclinical Models

CD25 Targeting Eliminates Regulatory T Cells and CD25+ Blasts in Acute Myeloid Leukemia

Pharmacologic Inhibitors of STAT3 or BCL6 Transcriptional Function Sensitize Lymphoma Cells to the Novel PD-1 Cis-Targeted PD1-IL2v Immunocytokine in a Murine Model

RG6234: A Novel 2:1 GPRC5D T Cell Bispecific Antibody Exhibits Best in Class Potential for the Treatment of Multiple Myeloma As a Monotherapy and in Combination

Targeting intracellular WT1 in AML with a novel RMF-peptide-MHC-specific T-cell bispecific antibody

Augmenting Efficacy of T-Cell Bispecific Antibodies in AML through a Tumor Stroma-Targeted 4-1BB Agonist

RG6076 (CD19-4-1BBL): CD19-Targeted 4-1BB Ligand Combination with Glofitamab As an Off-the-Shelf, Enhanced T-Cell Redirection Therapy for B-Cell Malignancies

Long-Term Results from a Phase 1b Study of Avadomide in Combination with Obinutuzumab in Patients with Relapsed and/or Refractory B-Cell Non-Hodgkin Lymphoma

Lymphoma Microenvironment Deconvolution Links M1 Macrophage Infiltration to Clinical Outcome in Diffuse Large B-Cell Lymphoma

Optimizing Ex-Vivo Expanded NK Cell- Mediated Antibody-Dependent Cellular Cytotoxicity (ADCC) Combined with NKTR-255 in Chronic Lymphocytic Leukemia (CLL), Follicular Lymphoma (FL), and Burkitt Lymphoma (BL)

Polatuzumab Vedotin, an Antibody-Drug Conjugate Targeting CD79b, Is a Highly Active Agent Against Burkitt Lymphoma and Primary Mediastinal B-Cell Lymphoma

Targeting Intracellular WT1 in AML Utilizing a T Cell Bispecific Antibody Construct: Augmenting Efficacy through Combination with Lenalidomide

Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only